MedTrace Logo

Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma

NCT00554905 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2009-02-10

No results posted yet for this study

Summary

The purpose of this study is to prospectively evaluate whether combined RFA and TACE (RFA-TACE) result in better survival outcomes than RFA alone in patients with HCC.

Conditions

Interventions

PROCEDURE

Radiofrequency ablation

For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, California, USA) and a needle electrode with a 15-gauge insulated cannula with 10 hook-shape expandable electrode tines with a diameter of 3.5cm at expansion (LeVeen; RadioTherapeutics, Mountain View, California, USA).

PROCEDURE

TACE

TACE first, then RFA within 2 weeks

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Min-Shan Chen, Doctor · Department of Hepatobilliary Surgery, Cancer Center, Sun Yat-sen University

  • Jin-Qing Li, Doctor · Department of Hepatobilliary Surgery, Cancer Center, Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2009-02-28
Completion
2009-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00554905 on ClinicalTrials.gov